Journal Mobile Options
Table of Contents
Vol. 12, No. 1, 2005
Issue release date: March 2005

ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in Schizophrenia

Krönig H. · Riedel M. · Schwarz M.J. · Strassnig M. · Möller H.-J. · Ackenheil M. · Müller N.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: We have previously reported reduced serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) in schizophrenic patients. A single-nucleotide polymorphism (SNP) of the ICAM-1 gene was described at position 241. The G→A SNP results in a nonsynonymous amino acid exchange of the ICAM-1 protein, and the A allele was shown to be also associated with several immunological disorders like rheumatoid arthritis. Methods: We investigated 70 schizophrenic patients and 128 unrelated healthy control persons regarding the relationship between the serum levels of sICAM-1 and the ICAM-1 G214A polymorphism. Results: We were able to replicate our previous finding of reduced sICAM-1 levels in schizophrenia. Healthy control persons carrying the polymorphic A allele showed markedly lower sICAM-1 serum levels than carriers of the homozygous GG wild type (p < 0.004). In contrast, no significant difference in the sICAM-1 serum levels were seen regarding the G241A genotype distribution in schizophrenic patients. Conclusion: We hypothesize that the biochemical effect of the G241A SNP is masked in schizophrenic patients, indicating a disease-related mechanism leading to reduced levels of sICAM-1 in schizophrenia.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T: Comparing patterns and costs of schizophrenia care in five European countries: The EPSILON Study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand 2002;105:42–54.
  2. Tsuang M: Schizophrenia: Genes and environment. Biol Psychiatry 2000;47:210–220.
  3. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS: Autoimmunity in schizophrenia: A review of recent findings. Ann Med 1993;25:489–496.
  4. Heath RG, McCarron KL, O’Neil CE: Antiseptal brain antibody in IgG of schizophrenic patients. Biol Psychiatry 1989;25:725–733.
  5. Sundin U, Thelander S: Antibody reactivity to brain membrane proteins in serum from schizophrenic patients. Brain Behav Immun 1989;3:345–358.
  6. Henneberg AE, Horter S, Ruffert S: Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 1994;14:15–22.
  7. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Müller N: Antibodies to heat shock proteins in schizophrenic patients: Implications for the mechanism of the disease. Am J Psychiatry 1999;156:1103–1104.
  8. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H: Immunological dysfunction in schizophrenia: A systematic approach. Neuropsychobiology 1998;37:186–193.
  9. Schwarz MJ, Chiang S, Müller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001;15:340–370.
  10. Lamphear JG, Stevens KR, Rich RR: Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule. J Immunol 1998;160:615–623.
  11. Hogg N, Leitinger B: Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J Leukoc Biol 2001;69:893–898.
  12. Schwarz MJ, Riedel M, Ackenheil M, Müller N: Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 2000;47:29–33.
  13. Riedel M, Krönig H, Schwarz MJ, Engel RR, Sikorski C, Kühn KU, Behrens S, Möller HJ, Ackenheil M, Müller N: Investigation of the ICAM-1 G241A and A469G gene polymorphisms in schizophrenia. Mol Psychiatry 2003;8:257–258.
  14. Macchioni P, Boiardi L, Casali B, Nicoli D, Farnetti E, Salvarani C: Intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in Italian patients with rheumatoid arthritis. Clin Exp Rheumatol 2000;18:553–558.
  15. Boiardi L, Salvarani C, Casali B, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Govoni M, Trotta F, Filippini D, Paolazzi G, Nicoli D, Farnetti E, Macchioni L: Intercellular adhesion molecule-1 gene polymorphisms in Behçet’s disease. J Rheumatol 2001;28:1283–1287.
  16. Salvarani C, Casali B, Boiardi L, Ranzi A, Macchioni P, Nicoli D, Farnetti E, Brini M, Portioli I: Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: Association with disease risk and severity. J Rheumatol 2000;27:1215–1221.
  17. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI: Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995;109:440–448.
  18. Braun C, Zahn R, Martin K, Albert E, Folwaczny C: Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin Immunol 2001;101:357–360.
  19. Aydintug AO, Tokgoz G, Ozoran K, Duzgun N, Gurler A, Tutkak H: Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behçet’s disease. Rheumatol Int 1995;15:75–78.
  20. Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernandez-Rodriguez J, Yague J, Urbano-Marquez A, Grau JM, Cid MC: Circulating soluble adhesion molecules in patients with giant cell arteritis: Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999;58:189–192.
  21. Göke M, Hoffmann JC, Evers J, Krüger H, Manns MP: Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol 1997;32:480–486.
  22. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL: A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997;36:164–169.
  23. Vora DK, Rosenbloom CL, Beaudet AL, Cottingham RW: Polymorphisms and linkage analysis for ICAM-1 and the selectin gene cluster. Genomics 1994;21:473–477.
  24. Butcher JN, Dahlstrom WG, Graham JR, Tellegen A, Kaemmer B: Minnesota Multiphasic Personality Inventory (MMPI-2) Manual for Administering and Scoring. Minneapolis, University of Minnesota Press, 1989.
  25. Angleitner A: Testrezension zu Minnesota Multiphasic Personality Inventory (MMPI). Z Differ Diagn Psychol 1997;18:4–10.
  26. Ponthieux A, Lambert D, Herbeth B, Droesch S, Pfister M, Visvikis S: Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort. Eur J Hum Genet 2003;11:679–686.
  27. Wenzel K, Ernst M, Rohde K, Baumann G, Speer A: DNA polymorphisms in adhesion molecule genes – a new risk factor for early atherosclerosis. Hum Genet 1996;97:15–20.
  28. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD: A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3788–3793.
  29. Seth R, Raymond FD, Makgoba MW: Circulating ICAM-1 isoforms: Diagnostic prospects for inflammatory and immune disorders. Lancet 1991;338:83–84.
  30. Komatsu S, Flores S, Gerritsen ME, Anderson DC, Granger DN: Differential upregulation of circulating soluble and endothelial cell intercellular adhesion molecule-1 in mice. Am J Pathol 1997;151:205–214.
  31. Budnik A, Grewe M, Gyufko K, Krutmann J: Analysis of the production of soluble ICAM-1 molecules by human cells. Exp Hematol 1996;24:352–359.
  32. Gearing AJ, Newman W: Circulating adhesion molecules in disease. Immunol Today 1993;14:506–512.
  33. Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ: Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993;43:15–21.
  34. Trojano M, Avolio C, Simone IL, Defazio G, Manzari C, De Robertis F, Calo A, Livrea P: Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: Correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 1996;47:1535–1541.
  35. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K: Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326–333.
  36. Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks JB, Hendricks C, Mehta JL: Alterations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996;132:1–8.
  37. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P: Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402–1408.
  38. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H: Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995;15:237–242.
  39. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996;246:279–284.
  40. Arolt V, Rothermundt M, Wandinger KP, Kirchner H: Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000;5:150–158.
  41. Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M: Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001;49:439–445.
  42. Paolieri F, Battifora M, Riccio AM, Pesce G, Canonica GW, Bagnasco M: Intercellular adhesion molecule-1 on cultured human epithelial cell lines: Influence of proinflammatory cytokines. Allergy 1997;52:521–531.
  43. Hilkens CM, Snijders A, Snijdewint FG, Wierenga EA, Kapsenberg ML: Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur Respir J Suppl 1996;22:90S–94S.
  44. Hinson RM, Williams JA, Shacter E: Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996;93:4885–4890.
  45. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029–1034.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50